SWOG S1616

Primary Category:

Treatment Protocols

Disease Category:

Melanoma, Metastatic Melanoma, Skin

Status:

Open

A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) OR Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti PD-L1 Agent

NCT#03033576